Selected article for: "cc NC ND International license and count function"
Author: Li Tan; Xia Kang; Xinran Ji; Qi Wang; Yongsheng li; Qiongshu Wang; Hongming Miao
Title: Validation of reported risk factors for disease classification and prognosis in COVID-19: a descriptive and retrospective study
  • Document date: 2020_4_7
    • ID: j90jc0rj_24
    Snippet: We validated that the LYM% could be a permissible predictor to identify critically ill, severe and moderate cases. Previous studies also supported the conclusion that lymphocyte count and function were closely related to the disease status of COVID-19 [11, 19] . Patients with insufficient immunity, including the elders and people with immunodeficiency, always presented a lower level of lymphocytes and a worse prognosis after infected with . CC-BY.....
    Document: We validated that the LYM% could be a permissible predictor to identify critically ill, severe and moderate cases. Previous studies also supported the conclusion that lymphocyte count and function were closely related to the disease status of COVID-19 [11, 19] . Patients with insufficient immunity, including the elders and people with immunodeficiency, always presented a lower level of lymphocytes and a worse prognosis after infected with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cc NC ND International license and disease status: 1, 2, 3
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cc NC ND International license and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cc NC ND International license and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • disease status and International license: 1, 2, 3, 4, 5
    • disease status and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • disease status and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • disease status and lymphocyte low level: 1
    • disease status and previous study: 1, 2, 3, 4, 5
    • function lymphocyte count and low level: 1, 2
    • function lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • function lymphocyte count and lymphocyte low level: 1, 2
    • function lymphocyte count and previous study: 1
    • immunodeficiency people and previous study: 1
    • insufficient immunity and low level: 1
    • International license and low level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • International license and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • International license and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14